• AstraZeneca submitted a US FDA application for Tagrisso with savolitinib in advanced lung cancer with MET overexpression or amplification following EGFR-targeted therapy.
• The combination reduced the risk of death by 32% versus chemotherapy in the Phase III SAFFRON trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261025577410) on October 25, 2026, and is solely responsible for the information contained therein.